Clinical Trials Logo

Clinical Trial Summary

This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a randomized controlled trial.


Clinical Trial Description

Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized. Extended proton pump inhibitor (PPI)-based sequential therapy as one of the most commonly used first-line regimens provides a satisfactory eradication rate of 90.7% (95% CI, 87.4% - 94.0%). Nevertheless, its complexity of the "sequential" usage is sometimes confusing to the patients and may lead to treatment failure. The emerging new regimen - vonoprazan-based triple therapy, on the other hand, is another appealing choice with simplicity, short treatment duration, and low pill burden. However, there's still no evidence regarding the use of vonoprazan-based triple therapy with high-dose amoxicillin (1000mg twice daily) as the first-line regimen. This study aimed to compare the efficacy of the current standard first-line regimen, sequential therapy, with that of vonoprazan-based triple therapy with high-dose Amoxicillin. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05371249
Study type Interventional
Source Fu Jen Catholic University Hospital
Contact
Status Active, not recruiting
Phase Phase 4
Start date December 1, 2021
Completion date February 28, 2024

See also
  Status Clinical Trial Phase
Completed NCT02892409 - TAK-438 Bismuth Drug Interaction Study Phase 1
Completed NCT05073367 - A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
Completed NCT00596401 - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting NCT04101708 - A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients Phase 4
Recruiting NCT04029415 - The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
Recruiting NCT04029493 - The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
Recruiting NCT04030715 - The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study N/A
Not yet recruiting NCT02933229 - The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Phase 4
Not yet recruiting NCT02934048 - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Phase 4
Recruiting NCT05184491 - Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management Phase 4
Recruiting NCT05790525 - Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy Phase 4
Completed NCT05790512 - Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Recruiting NCT05276557 - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study Phase 3
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting NCT05449028 - Helicobacter Pylori Eradication Therapy in Portugal N/A
Recruiting NCT00306280 - Feasibility Study of Phototherapy System to Treat H Pylori N/A
Active, not recruiting NCT02675010 - Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study N/A
Withdrawn NCT00467155 - Helicobacter in The Gambia (Part 2) N/A
Completed NCT03716622 - A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication Phase 4